New hires and promotions in the biopharma industry in Asia-Pacific, including: Clarity, Gracell, Lianbio.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Alebund, Cocrystal, Resverlogix, Shenzhen Hepalink, Summit Healthcare Acquisition, Valneva.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Adagio, Arch Biopartners, Ascletis, Astrazeneca, Bionomics, Daiichi Sankyo, Diffusion, Gennova, HDT, Humanigen, Immunic, Inovio, Isofol Medical, Moderna, Novavax, Telix, Vaxart.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Abcellera, Altimmune, Amphastar, Anixa, Applied DNA Sciences, Asieris, Beigene, Beijing Youfeng Biological Technology, Biontech, CSL Behring, Cytodyn, Effector, Esteve, Evvivax, Fortress, Fuji Yakuhin, Generex, Hcmed Innovations, Hoth, Hutchmed, Ibio, Inspira, ITM, Kowa, Lupin, Moderna, Molecular Partners, Molgenie, Nabriva Therapeutics Ireland, Nexturn, Nicox, Novavax, Ocugen, Olix, Ontochem, PCI, Pharmabcine, Recce, Roivant Sciences, Rosvivo, Samsung Bioepis, Sumitomo Dainippon, Takanawa Japan, Tiziana Life Sciences, Trevena, Vectura, Wuxi Biologics, Yiling.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Ampio, Astellas, Beigene, Biontech, Clarity, Eagle, Eli Lilly, Everest Medicines, GC, Glaxosmithkline, Hutchmed, Kyowa Kirin, Pfizer, RDIF, R-Pharm Germany, Vir.